Lanreotide
Also known as: Somatuline, Somatuline Depot, Autogel
At a glance
PeptiGuide dataset · reviewed Aug 2026
What it is
FDA-approved long-acting somatostatin analog for endocrine and neuroendocrine tumor contexts
Status
FDA Approved
Typical dose
60–120mg
Researched for
Acromegaly, neuroendocrine tumors, hormone control
Trial progress
- PrePreclinical
- IPhase I
- IIPhase II
- IIIPhase III
- IVPhase IV
- FDAFDA approved
FDA approved - FDA-approved for specific uses with established human evidence
Use the tools
Stay current
Get updates on Lanreotide
New studies, regulatory decisions and data corrections - delivered when they land.
In plain language
- Eight-amino-acid somatostatin analog related to octreotide.
- Long-acting Somatuline Depot/Autogel formulation given by deep injection.
- Source status: FDA approved, with listed clinical use areas including acromegaly, GEP-NETs, and carcinoid syndrome.
- Extracted typical dose: 60-120 mg every 4 weeks.
- Research areas listed: acromegaly, neuroendocrine tumors, and hormone control.
How it's thought to work
Lanreotide is described as a somatostatin analog with strongest receptor preference for SSTR2 and SSTR5 and weaker binding across SSTR1, SSTR3, and SSTR4. The source links SSTR2/SSTR5 activity in pituitary cells to reduced growth hormone release and lower IGF-1. In neuroendocrine tumor contexts, the evidence reports both reduced hormone over-secretion and direct growth-slowing activity. The long-acting gel depot is described as releasing the gradually, supporting an approximately four-week interval.
What the research shows
Where the research stands
The source describes a mature clinical evidence base. It highlights the CLARINET phase 3 trial in more than 200 patients with metastatic grade 1 or 2 enteropancreatic neuroendocrine tumors, reporting a 53 percent reduction in risk of progression or death and progression-free survival that was not reached, compared with about 18 months for placebo. For acromegaly, the supplied summary says multicenter studies found IGF-1 normalization and growth hormone reductions in a substantial share of patients, with results characterized as comparable to octreotide. The same source notes class-like adverse effects including diarrhea, gallstones, and injection-site reactions.
What it shows
✓ Human clinical evidence
FDA-approved for specific uses with established human evidence
△ Limitations
Use only according to approved labeling and qualified medical guidance.
Bottom line: FDA Approved - Acromegaly, GEP-NETs, and carcinoid syndrome FDA Approved
Typical dosing
CommunityCommunity dataset60–120 mg
every 4 weeks
Community-reported row describes a long-acting Somatuline Depot somatostatin analog administered by deep subcutaneous injection; it is not medical advice.
Research dosing
Indication-specificApproved for specific uses - study doses are indication-specific
Timing & administration
Best time to take
Morning or as directed
Follow recommended protocol
Food recommendation
With or without food
Why this timing?
The source indicates timing can differ by response and goals; maintaining a consistent schedule is presented as more important than a specific clock time.
Possible side effects
Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.
- Diarrhea
- Abdominal pain
- Nausea
- Injection site reactions
- Gallstones
- Hyperglycemia or hypoglycemia
- Bradycardia
Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.
Sources
Frequently asked questions
Sequence
H-D-2-Nal-Cys(1)-Tyr-D-Trp-Lys-Val-Cys(1)-Thr-NH2; Cys2-Cys7 disulfide
One open dataset
Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.
Browse the datasetEducational resource, not medical advice. Talk to your clinician before acting on anything here.
Community discussion
Comments are moderated before they appear. Keep it evidence-focused.